The ROMEO score demonstrated strong predictive performance for significant TTE findings within 30 days, with an AUC of 0.83 (95% CI 0.79-0.87) and 98.9% sensitivity for a score of zero.
Cohort (n=1,287)
Yes
Does the ROMEO score accurately predict significant echocardiography findings in adults presenting to the ED with syncope?
The ROMEO score demonstrates strong predictive performance (AUC 0.83, NPV 98.6%) and can safely identify ED syncope patients who are unlikely to benefit from routine echocardiography.
Effect estimate: AUC 0.83 (95% CI 0.79 to 0.87)
BACKGROUND: Syncope is common in the Emergency Department (ED) and can be associated with structural heart disease (SHD). Transthoracic echocardiography (TTE) is commonly ordered to assess for SHD. OBJECTIVE: To externally validate the previously developed ROMEO score, which identifies patients with syncope who are at very low risk of significant findings on TTE. DESIGN: Secondary analysis of a multicenter, prospective, observational cohort study. SETTING: One community and five academic EDs in the United States. PARTICIPANTS: Adults (≥ 40 years old) presenting to the ED with syncope or presyncope, without a serious ED diagnosis. INTERVENTIONS: Receipt of TTE within 30 days of the index visit. MEASUREMENTS: Our primary outcome was the rate of significant findings on TTE within 30 days of the index ED visit. We calculated the sensitivity, specificity, negative and positive predictive values (NPV, PPV), and the area under the curve (AUC) of the ROMEO score. RESULTS: We enrolled 1287 patients, of whom 427 underwent TTE. 88 (20.6%) had a significant finding. A ROMEO score of zero had a sensitivity of 98.9% and a NPV of 98.6%. The specificity and PPV were 20.2% and 24.3%, respectively. The AUC was 0.83 (95% CI: 0.79 to 0.87). LIMITATIONS: Given the rate of non-enrollment of screened patients, there is potential for selection bias. Our study sample was biased toward urban, academic centers; the results may not apply to community settings. CONCLUSIONS: The ROMEO score demonstrates strong predictive performance and may be useful to help clinicians identify patients who are unlikely to benefit from TTE. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT04533425.
DeAngelis et al. (Mon,) conducted a cohort in Syncope or presyncope (n=1,287). ROMEO score was evaluated on rate of significant findings on TTE within 30 days of the index ED visit (AUC 0.83, 95% CI 0.79 to 0.87). The ROMEO score demonstrated strong predictive performance for significant TTE findings within 30 days, with an AUC of 0.83 (95% CI 0.79-0.87) and 98.9% sensitivity for a score of zero.